Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway

PURPOSE: New direct-acting antiviral (DAA) drugs have revolutionized the treatment of hepatitis C in recent years. OBJECTIVE: Our objective was to analyse the cost effectiveness of combinations of different DAAs compared with ribavirin and peginterferon-α-2a, taking into account rebates from tender...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Pharmacoeconomics
Autors principals: Wisløff, Torbjørn, White, Richard, Dalgard, Olav, Amundsen, Ellen J., Meijerink, Hinta, Løvlie, Astrid Louise, Kløvstad, Hilde
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2018
Matèries:
Original Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5906515/
https://ncbi.nlm.nih.gov/pubmed/29396744
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-017-0604-3
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars